Sanofi Consumer Healthcare India Ltd
- Market Cap ₹ Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E
- Book Value ₹
- Dividend Yield %
- ROCE %
- ROE %
- Face Value ₹
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE Allcap
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Dividend Payout % |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Figures in Rs. Crores
| Equity Capital |
| Reserves |
| Total Liabilities |
| CWIP |
| Investments |
| Total Assets |
Cash Flows
Figures in Rs. Crores
| Net Cash Flow |
| Free Cash Flow |
| CFO/OP |
Ratios
Figures in Rs. Crores
| Debtor Days |
| Inventory Days |
| Days Payable |
| Cash Conversion Cycle |
| Working Capital Days |
| ROCE % |
Insights
In beta| Dec 2023 | Dec 2024 | |
|---|---|---|
| Allegra Market Share (Allergy Category) % ・Standalone data |
|
|
| Avil Market Share (Allergy Category) % ・Standalone data |
||
| City Reach Number of Cities ・Standalone data |
||
| Combiflam Annual Sales Volume Million Tablets ・Standalone data |
||
| Combiflam Market Share (Pain Category) % ・Standalone data |
||
| Combiflam Sales Velocity Strips per minute ・Standalone data |
||
| DePURA Market Share (Vitamin D Category) % ・Standalone data |
||
| Total Employees Number ・Standalone data |
||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
27 Mar - Transcript of the Institutional Investor Meet held on Tuesday, 24th March 2026 is enclosed.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
26 Mar - Video recording of SCHIL Institutional Investor Meet held 24 March 2026 available on company website.
- Closure of Trading Window 25 Mar
- Announcement under Regulation 30 (LODR)-Investor Presentation 24 Mar
-
Publication of Postal Ballot Notice
24 Mar - Postal ballot (dispatched 23 Mar 2026); e-voting 24 Mar–22 Apr; approvals for Opella RPTs and director remuneration limits and amendment to MD pay terms; voting …
Annual reports
Concalls
-
Mar 2026Transcript PPT
Business Overview:[1][2]
SCHIL was formed following its demerger from Sanofi India Limited, to establish a standalone Consumer Healthcare (CHC) business. It operates in the Consumer Healthcare (CHC) sector, providing self-care solutions across various health categories including allergy relief, pain management, and wellness